Unfortunately, modern technology hasn’t yet found a cure for Type-1 diabetes. However, latest innovations in the medical field can help patients regain their lost quality of life. One of the new solutions entails a smart upgrade applied at the level of the pancreas. People can then monitor their condition in real time through just a mobile app.
The Experimental Study Recorded Drop in A1c and Decreased Hypoglycemia States
People with type-1 diabetes have to go through life-changing experiences. Instead of enjoying a meal, they have to track down their blood sugar levels and inoculate themselves with the right amount of insulin. As a result, the treatment will last for an entire life, is intrusive, disruptive, and needs attention to details.
However, an international team of researchers is about to restore the control of type-1 diabetes patients over their own lifestyles. Their experimental project entails giving the pancreas a smart upgrade to keep track of a person’s condition in real time.
The outpatient trial led by Frank Doyle and Eyal Dassau of the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) recorded great improvements. Participants showed a drop in hemoglobin A1c (HbA1c) and decreased timeframe spent in hypoglycemia.
The Smart Upgrade of the Pancreas Will Be Able to Create an Automatic Insulin Delivery
The novel treatment consists of an operation where physicians connect an insulin pump to the pancreas. They also insert a continuous glucose monitor right under the screen. The resulted artificial system will be able to communicate with a mobile device through a Bluetooth connection. The system can receive wireless signals with different orders that instruct it to deliver the right dose of hormone.
This way, people who have type-1 diabetes will be able to skip daily injections. On top of that, their mobile apps will feature special algorithms that can measure the right daily doses of insulin on their own. The smart upgrade the pancreas received will take care of the rest.
The study included 30 participants that were monitored for 12 weeks. While primary results are satisfactory, such intrusive treatments often need to dedicate a lot of time to tests. The market might receive such an automatic insulin delivery in a matter of months or even years.
Image source: 1